KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pacific Biosciences Of California (PACB) Research & Development (2016 - 2026)

Pacific Biosciences Of California has reported Research & Development over the past 16 years, most recently at $22.9 million for Q4 2025.

  • For Q4 2025, Research & Development fell 16.7% year-over-year to $22.9 million; the TTM value through Dec 2025 reached $97.3 million, down 27.88%, while the annual FY2025 figure was $97.3 million, 27.88% down from the prior year.
  • Research & Development for Q4 2025 was $22.9 million at Pacific Biosciences Of California, roughly flat from $22.8 million in the prior quarter.
  • Over five years, Research & Development peaked at $52.9 million in Q1 2022 and troughed at $20.5 million in Q1 2021.
  • A 5-year average of $36.7 million and a median of $42.6 million in 2021 define the central range for Research & Development.
  • Biggest five-year swings in Research & Development: skyrocketed 157.63% in 2022 and later crashed 46.3% in 2024.
  • Year by year, Research & Development stood at $42.6 million in 2021, then grew by 0.11% to $42.6 million in 2022, then increased by 4.51% to $44.5 million in 2023, then crashed by 38.34% to $27.5 million in 2024, then fell by 16.7% to $22.9 million in 2025.
  • Business Quant data shows Research & Development for PACB at $22.9 million in Q4 2025, $22.8 million in Q3 2025, and $22.5 million in Q2 2025.